BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

647 related articles for article (PubMed ID: 28774421)

  • 1. Thalassaemia.
    Taher AT; Weatherall DJ; Cappellini MD
    Lancet; 2018 Jan; 391(10116):155-167. PubMed ID: 28774421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beta-thalassemia and the advent of new interventions beyond transfusion and iron chelation.
    Chauhan W; Shoaib S; Fatma R; Zaka-Ur-Rab Z; Afzal M
    Br J Clin Pharmacol; 2022 Aug; 88(8):3610-3626. PubMed ID: 35373382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transfusion support for haemoglobinopathies.
    Greenwalt TJ; Zelenski KR
    Clin Haematol; 1984 Feb; 13(1):151-65. PubMed ID: 6373080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thalassaemia.
    Higgs DR; Engel JD; Stamatoyannopoulos G
    Lancet; 2012 Jan; 379(9813):373-83. PubMed ID: 21908035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal management of β thalassaemia intermedia.
    Taher AT; Musallam KM; Cappellini MD; Weatherall DJ
    Br J Haematol; 2011 Mar; 152(5):512-23. PubMed ID: 21250971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A paradigm shift on beta-thalassaemia treatment: How will we manage this old disease with new therapies?
    Cappellini MD; Porter JB; Viprakasit V; Taher AT
    Blood Rev; 2018 Jul; 32(4):300-311. PubMed ID: 29455932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. When to consider transfusion therapy for patients with non-transfusion-dependent thalassaemia.
    Taher AT; Radwan A; Viprakasit V
    Vox Sang; 2015 Jan; 108(1):1-10. PubMed ID: 25286743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification and key management of non-transfusion-dependent thalassaemia patients: not a rare but potentially under-recognised condition.
    Viprakasit V; Tyan P; Rodmai S; Taher AT
    Orphanet J Rare Dis; 2014 Sep; 9():131. PubMed ID: 25265971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Co-inheritance of alpha- and beta-thalassaemia in mice ameliorates thalassaemic phenotype.
    Voon HP; Wardan H; Vadolas J
    Blood Cells Mol Dis; 2007; 39(2):184-8. PubMed ID: 17493845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iron overload across the spectrum of non-transfusion-dependent thalassaemias: role of erythropoiesis, splenectomy and transfusions.
    Porter JB; Cappellini MD; Kattamis A; Viprakasit V; Musallam KM; Zhu Z; Taher AT
    Br J Haematol; 2017 Jan; 176(2):288-299. PubMed ID: 27917462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thalassaemia.
    Kattamis A; Kwiatkowski JL; Aydinok Y
    Lancet; 2022 Jun; 399(10343):2310-2324. PubMed ID: 35691301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Morbidities in non-transfusion-dependent thalassemia.
    Saliba AN; Taher AT
    Ann N Y Acad Sci; 2016 Mar; 1368(1):82-94. PubMed ID: 27186941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel therapies in β-thalassaemia.
    Grech L; Borg K; Borg J
    Br J Clin Pharmacol; 2022 Jun; 88(6):2509-2524. PubMed ID: 34004015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erythrokinetics and iron status in heterozygous beta thalassaemia, and the effect of interaction with alpha thalassaemia.
    Pippard MJ; Wainscoat JS
    Br J Haematol; 1987 May; 66(1):123-7. PubMed ID: 3593648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hematopoietic stem cell transplantation for people with ß-thalassaemia major.
    Jagannath VA; Fedorowicz Z; Al Hajeri A; Sharma A
    Cochrane Database Syst Rev; 2014 Oct; (10):CD008708. PubMed ID: 25316103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hematopoietic stem cell transplantation for people with ß-thalassaemia major.
    Jagannath VA; Fedorowicz Z; Al Hajeri A; Hu N; Sharma A
    Cochrane Database Syst Rev; 2011 Oct; (10):CD008708. PubMed ID: 21975785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent trends in treatment of thalassemia.
    El-Beshlawy A; El-Ghamrawy M
    Blood Cells Mol Dis; 2019 May; 76():53-58. PubMed ID: 30792169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deferasirox for managing iron overload in people with thalassaemia.
    Meerpohl JJ; Antes G; Rücker G; Fleeman N; Motschall E; Niemeyer CM; Bassler D
    Cochrane Database Syst Rev; 2012 Feb; (2):CD007476. PubMed ID: 22336831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.
    Roberts DJ; Rees D; Howard J; Hyde C; Alderson P; Brunskill S
    Cochrane Database Syst Rev; 2005 Oct; (4):CD004450. PubMed ID: 16235363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An update on the US adult thalassaemia population: a report from the CDC thalassaemia treatment centres.
    Chapin J; Cohen AR; Neufeld EJ; Vichinsky E; Giardina PJ; Boudreaux J; Le BC; Kenney K; Trimble S; Thompson AA
    Br J Haematol; 2022 Jan; 196(2):380-389. PubMed ID: 34775608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.